CTLA4 and nonpapillary renal cell carcinoma: In addition, ccRCC shows sensitivity to immune checkpoint inhibitors (ICIs), including those blocking programmed death-1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (9).